- Home
- CNNE vs ABUS Comparison
CNNE vs ABUS Comparison
Compare CNNE & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNNE | ABUS |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 844.8M | 848.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CNNE | ABUS |
|---|---|---|
| Price | $16.38 | $4.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $22.25 | $5.00 |
| AVG Volume (30 Days) | 729.0K | ★ 1.1M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $430,200,000.00 | $14,606,000.00 |
| Revenue This Year | N/A | $125.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 116.64 |
| 52 Week Low | $15.05 | $2.71 |
| 52 Week High | $21.96 | $5.10 |
Technical Indicators
Market Signals| Indicator | CNNE | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 50.01 |
| Support Level | $15.64 | $4.09 |
| Resistance Level | $16.90 | $4.47 |
| Average True Range (ATR) | 0.41 | 0.20 |
| MACD | 0.20 | -0.00 |
| Stochastic Oscillator | 73.51 | 54.18 |
Price Performance
Historical ComparisonAbout CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.